N
Noetik
AI-driven biotechnology company developing precision immunotherapies for cancer using advanced machine learning and human multimodal data
About Noetik
Noetik.ai is an AI-native biotechnology company focused on revolutionizing cancer treatment through the development of precision immunotherapies. The company leverages advanced machine learning techniques to analyze complex tumor-immune interactions, which traditional reductionist approaches fail to capture. By combining self-supervised learning with the large-scale generation of human multimodal data, Noetik aims to create foundational models for cell and tissue biology that drive therapeutic development. This innovative approach allows Noetik to enter a new era of drug discovery, where AI is not just used to enhance human tasks but to achieve what humans alone cannot. Noetik serves the biotechnology and pharmaceutical sectors, targeting clients who are looking for cutting-edge cancer treatment solutions. The company operates in the precision medicine market, focusing on immunotherapies tailored to individual patients. Noetik's business model involves partnering with pharmaceutical companies and healthcare providers to develop and commercialize its AI-driven therapies. Revenue is generated through licensing agreements, research collaborations, and the sale of proprietary therapeutic solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- South San Francisco, United States
- Employees
- 49
- Open positions
- 1
- Dealroom signal
- 90.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2024 | $40M | $160M | EPIC Ventures · DCVC · Jean-Francois Gagné · Catalio Capital Management | ↗ |
| SEEDOther financing | Sep 2023 | $14M | $56M | Hummingbird Ventures · Zetta Venture Partners · EPIC Ventures · Viswa Colluru | ↗ |
Growth signals
Latest recorded traffic for Noetik is 13K monthly website visits, up 0% over the last three months. Noetik's team grew 19.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed13 investors entered at this stage
DCVC
Hummingbird Ventures
Zetta Venture Partners
EPIC Ventures- VCViswa Colluru
Intermountain Ventures- CBCJNV BioVenture
- MSMichael Secora
11.2 Capital
Chris Gibson
Catalio Capital Management
North South Ventures
Chau Khuong
Series A8 investors entered at this stage
Amy Schulman
Polaris Partners
Jean-Francois Gagné
Wittington Ventures
Linearis
Khosla Ventures
Breakout Ventures
ApSTAT Technologies
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Noetik on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Noetik’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.